Real-World Use of Dinutuximab Beta for High-Risk Neuroblastoma in Clinical Settings in France: The QUATUOR Study
Authors:
- Anne-Sophie DefachellesADAnne-Sophie Defachelles
- Gudrun SchleiermacherGudrun Schleiermacher
- Dominique PlantazDPDominique Plantaz
- Stéphanie ProustSPStéphanie Proust
- Sarah BenezechSBSarah Benezech
- Marianna DeparisMDMarianna Deparis
- Ludovic MansuyLMLudovic Mansuy
- Joy BenadibaJBJoy Benadiba
- Julie TandonnetJTJulie Tandonnet
- Estelle ThebaudETEstelle Thebaud
- Sarah JannierSJSarah Jannier
- Chrystelle DuprazCDChrystelle Dupraz
Open Access
- 15 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
Abstract
Dinutuximab beta (DB) is recommended for maintenance therapy in high-risk neuroblastoma (HR-NB) in Europe. In France, early access to DB was provided in the Temporary Use Authorization (ATU) program. The QUATUOR (Qarziba Use ATU Outcomes Research) study is an observational, multicenter, retrospective study that evaluated the effectiveness and safety of DB in HR-NB patients who received DB in maintenance between February 2017 and August 2018 in real-world clinical settings in France as part of the ATU program. Fourteen patients received DB in the frontline and 17 in the refractory/relapsed setting. In the frontline group, 2-year EFS and OS rates were 64.3% (95% CI: 34.3-83.3%) and 78.6% (95% CI: 47.3-92.5%), respectively, and in the relapsed/refractory group, 57.5% (95% CI: 30.7-77.2%) and 80.9% (95% CI: 51.3-93.5%), respectively. Complete or partial response of the metastatic sites was maintained by 23/31 evaluable patients at the end of treatment. Overall, DB was effective, with acceptable tolerability, in patients with HR-NB treated as part of the ATU program in France. This study demonstrates the importance of successful collaboration between national health authorities, pharmaceutical companies, physicians, and the neuroblastoma community to provide early access to innovative treatments.Keywords
Funding Information
- Recordati Rare Diseases
This publication has 20 references indexed in Scilit:
- Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?European Journal of Cancer, 2024
- Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingCancer, 2022
- Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical GuidancePediatric Drugs, 2021
- The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncologyEuropean Journal of Cancer, 2021
- A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastomaEuropean Journal of Cancer, 2019
- Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2018
- Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialThe Lancet Oncology, 2017
- NeuroblastomaNature Reviews Disease Primers, 2016
- 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panelEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Neuroblastoma: Biology, Prognosis, and TreatmentHematology/Oncology Clinics of North America, 2010